Abstract: The present invention relates to a polypeptide construct comprising at least two fragments of an allergen from the Amb a 1 family of allergens from Ambrosia atermisiifolia or variants of said at least two fragments, wherein each of the at least two fragments consist of 20 to 50 amino acid residues and wherein at least one fragment is derived from amino acid residues 1 to 50 of the mature allergen and at least one fragment is derived from amino acid residues 240 and ending at the C-terminal end of the mature allergen.

Abstract: The present invention relates to a polypeptide construct comprising at least two fragments of an allergen from the Amb a 1 family of allergens from Ambrosia atermisiifolia or variants of said at least two fragments, wherein each of the at least two fragments consist of 20 to 50 amino acid residues and wherein at least one fragment is derived from amino acid residues 1 to 50 of the mature allergen and at least one fragment is derived from amino acid residues 240 and ending at the C-terminal end of the mature allergen.

Abstract: A coating formed on a substrate is provided which coating comprises (a) an organic NIR-transparent pigment and/or an inorganic NIR-reflective pigment; (b) a dye having a transmittance of at least 75% in the range of from 700 to 2500 nm; and (c) optionally an effect pigment; wherein said coating exhibits a total solar reflectance (TSR) of (i) ?40%, if 60<L*<100, or (ii) ?30%, if 30<L*?60, or (iii) ?20%, if 0<L*?30, wherein L* is the lightness. The coating is suitable for an exterior-use coating like an industrial coating or a coating for vehicles, especially an automotive finish, having improved jetness.

Abstract: A coating formed on a substrate is provided which coating comprises (a) an organic NIR-transparent pigment and/or an inorganic NIR-reflective pigment; (b) a dye having a transmittance of at least 75% in the range of from 700 to 2500 nm; and (c) optionally an effect pigment; wherein said coating exhibits a total solar reflectance (TSR) of (i) ?40%, if 60<L*<100, or (ii) ?30%, if 30<L*?60, or (iii) ?20%, if 0<L*?30, wherein L* is the lightness. The coating is suitable for an exterior-use coating like an industrial coating or a coating for vehicles, especially an automotive finish, having improved jetness.

Abstract: Peptides, peptidomimetics and derivatives thereof of the general formula I: H2N-GHRPX1-?-X4X5X6X7X8X9X10-X11?(I), in which X1-X10 denote one of the 20 genetically coded amino acids, wherein X8, X9 and X10 may also denote a single chemical bond; X11 denotes OR1 in which R1 equals hydrogen or (C1-C10) alkyl NR2R3 with R2 and R3 are equal or different and denote hydrogen, (C1-C10) alkyl, or a residue —W-PEG5-60K, in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y—Z-PEG5-60K, in which Y denotes a chemical bond or a genetically coded amino acids from the group S, C, K or R and Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, and their physiologically acceptable salts, and ? denotes an amino acid, or a peptidomimetic element, which induces a bend or turn in the peptide backbone.

Abstract: The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides.

Abstract: Peptides and peptide derivatives of the following general Formula (I): H2N-GHRPX1X2X3X4X5X6X7X8X9X10X11PX12PPPX13X14X15X16GYR—X17 (I), wherein: X1-X16 denote one of the 20 genetically encoded amino acids, X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl, or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof, or wherein: X15 or X16 denotes an amino acid from the group of C or K, which is linked to a residue Z-PEG5-60K via the heteroatom in the side chain, and wherein X17 denotes OR1, with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen or (C1-C10)-alkyl, as we

Abstract: The invention is concerned with the use of a peptide comprising the N-terminal sequence Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala- Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (SEQ ID NO: 1) or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the B?-chain (i.e. B?15-42) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.

Abstract: The invention is directed to compounds and methods for prevention and/or treatment of inflammation using the same.

Abstract: A method of finishing an organic pigment that involves dissolving or dispersing the pigment in a mineral acid and crystallizing the pigment from the solution or dispersion by mixing with an aqueous diluent in the absence of a sulfonato-functional condensation product of an arylsulfonic acid and an aliphatic aldehyde as crystallization inhibitor, which comprises ripening the crystallized organic pigment in the presence of a surfactant or in the presence of a pigment solubility enhancer in aqueous suspension.

Abstract: Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

Abstract: The present invention is directed to methods for treatment and/or prevention of a disease associated with vascular leak in a patient comprising administering to the patient an effective amount of SEQ ID NO: 1.

Abstract: Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

Abstract: The invention relates to peptides and peptide derivatives of the following general Formulas Ia and Ib as well as in particular anti-inflammatory drugs containing these peptides.

Abstract: The invention is directed to compositions and methods for using the same for the prevention and treatment of hypoxic conditions, ischemia/reperfusion injury and the sequels thereof.

Abstract: Peptides, peptidomimetics and derivatives thereof of the general formula I: H2N-GHRPX1-?-X4X5X6X7X8X9X10-X11 (I), in which X1-X10 denote one of the 20 genetically coded amino acids, wherein X8, X9 and X10 may also denote a single chemical bond; X11 denotes OR1 in which R1 equals hydrogen or (C1-C10) alkyl NR2R3 with R2 and R3 are equal or different and denote hydrogen, (C1-C10) alkyl, or a residue —W-PEG5-60K, in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y-Z-PEG5-60K, in which Y denotes a chemical bond or a genetically coded amino acids from the group S, C, K or R and Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, and their physiologically acceptable salts, and ? denotes an amino acid, or a peptidomimetic element, which induces a bend or turn in the peptide backbone.

Abstract: The invention relates to a methods finishing an organic pigment by dissolving or dispersing the pigment in a mineral acid and crystallizing the pigment from the solution or dispersion by mixing with an aqueous diluent in the presence of a crystallization modifier constituted by a sulfonate-functional condensation product of a naphthalenesulfonic acid and at least one aliphatic aldehyde having 1 to 6 carbon atoms, and then isolating the pigment as a solid, wherein the crystallization modifier is present in the aqueous diluent.

Abstract: The invention relates to a method of finishing an organic pigment that involves dissolving or dispersing the pigment in an aqueous solvent or a mineral acid and crystallizing the pigment from the solution or dispersion in the presence of a crystallization modifier, and subsequently isolating the pigment as a solid, wherein the crystallization modifier is a condensation product containing sulfonate groups and formed from at least one hydroxyarylsulfonic acid and/or at least one hydroxydiaryl sulfone compound and at least one aliphatic aldehyde having 1-6 C atoms, optionally urea, and an alkali metal sulfite if appropriate, or is a mixture of such condensation products.

Abstract: Peptides and derivatives thereof of the following general formula I: (SEQ ID NO: 1) (I) H2N-GHRPX1X2PX3X4X5PX6PPPX7X8X9X10B(1)B(2)B(3)- X11, wherein: B(1) denotes either a chemical bond or the amino acid G B(2) denotes either a chemical bond or the amino acid Y B(3) denotes either a chemical bond or the amino acid R X1—X10 denote one of the 20 genetically encoded amino acids, X11 denotes OR1 with R1=hydrogen or (C1-C10-alkyl), or NR2R3, R2 and R3 being identical or different and denoting hydrogen, (C1-C10)-alkyl or a residue -PEG5-60K, wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH—Y-Z-PEG5-60K, wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof.

Abstract: Peptides, peptidomimetics and derivatives thereof of the following general formula I: (SEQ ID NO: 1) (I) H2N-GHRPX1X2X3-?-X4X5X6X7X8X9X10-X11, in which X1-X10 denote one of the 20 genetically coded amino acids, wherein X8, X9 and X10 individually or jointly may also denote a single chemical bond X11 denotes OR1 in which R1 equals hydrogen or (C1-C10)alkyl NR2R3 with R2 and R3 are equal or different and denote hydrogen, (C1-C10)alkyl or a residue —W-PEG5-60K, in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y-Z-PEG5-60K, in which Y denotes a single chemical bond or a genetically coded amino acids from the group S, C, K or R and in which Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, as well as their physiologically acceptable salts, and in which additionally ? denotes an amino acid, whether genetically coded or not, or a peptidomimetic element, which have the additional property of inducing a bend or